Exploration of Digestive Diseases

Table 1

Studies (n = 13) evaluating liver stiffness by VCTE and HCC occurrence in HBV patients. Composite model comprising VCTE

Author & year	Region	Virological status	Patients (n)	Mean age (years)	F-U months	HCC (n)	Prevalence (%)	Proposed cut-off (kPa)	AUROC	Sens (%)	Spec (%)	PPV	NPV	LR+	LR–
Jung et al., 2011 [13]	Korea	Mixed	1,130	50.2	31	57	5	8	-	-	-	-	-	-	-
Chon et al., 2012 [11]	Korea	Mixed	1,126	50.2	30.7	63	5.5	-	0.789	-	-	-	-	-	-
Kim et al., 2012 [14]	Korea	No therapy at baseline	128	52.5	27.8	14	11	≥ 19	0.722	61.1	86.2	-	-	4.36	0.45
Kim et al., 2013 [15]	Korea	Mixed	1,250	50	30.7	56	4.5	-	0.802	-	-	-	-	-	-
Wong et al., 2014 [16]	China	Mixed	1,555	46 ± 12	69	55	3.5	≥ 11	0.89	87.9		-	99.4	-	-
Kim et al., 2015 [17]	Korea	Mixed	2,876	46.1	48.9	52	1.8	≥ 13	-	-	-	-	-	-	-
Bihari et al., 2016 [18]	Asia	Mixed	964	38.6 ± 14.6	-	14	1.4	-	0.767*	-	-	-	-	-	-
Seo et al., 2016 [10]	Asia	No therapy at baseline	381	44.1 ± 12.3	48.1	34	8.9	-	0.745	-	-	-	-	-	-
Jeon et al., 2017 [19]	Korea	Mixed	540	51.5	54.1	81	15	≥ 13	0.598	-	-	-	-	-	-
Li et al., 2017 [20]	China	Viral suppression	1,200	40–59	-	156	13	≥ 9.7	-	-	-	-	-	-	-
Izumi et al., 2019 [21]	Japan	Mixed	377	-	27	23	6	≥ 6.2	0.79520	73.9	82.2	21.3	98	4.11	0.31
Wang et al., 2019 [12]	Taiwan, China	Viral suppression	257	52.6	45.6	27	10	≥ 21.5	0.636	55.6	64.2	-	-	1.5	0.68
Lee et al., 2021 [22]	Korea	Viral suppression	880	53.1	24	81	9	≥ 6.4	-	-	-	-	-	-	-

*: composite outcome; VCTE: vibration-controlled transient elastography